E84.11 Meconium ileus in cystic fibrosis

Name of the Condition

• Meconium Ileus in Cystic Fibrosis (ICD-10 Code: E84.11)

Summary

Meconium ileus in cystic fibrosis is a gastrointestinal complication of cystic fibrosis characterized by intestinal obstruction caused by thick, sticky meconium in newborns. This condition results from abnormal mucus production due to CFTR gene mutations, leading to impaired pancreatic and intestinal function. It requires prompt diagnosis and management to prevent bowel damage and associated complications.

Causes

Meconium ileus in cystic fibrosis is caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene, which disrupts salt and water transport in cells. These mutations lead to defective CFTR protein function, resulting in thick, dehydrated meconium that obstructs the small intestine. The disorder follows an autosomal recessive inheritance pattern, requiring two mutated gene copies for development.

Risk Factors

• Family history of cystic fibrosis.
• Being of Northern European descent (higher prevalence).
• Carrying one copy of the CFTR mutation (carrier status).

Symptoms

• Failure to pass meconium within 24-48 hours of birth.
• Abdominal distension or bloating.
• Vomiting (often bilious or feculent).
• Poor feeding or feeding intolerance.
• Dehydration or electrolyte imbalances.

Diagnosis

Diagnosis involves clinical evaluation of newborns with failure to pass meconium, supported by imaging studies such as abdominal X-rays (showing dilated bowel loops or "soap bubble" appearance) or contrast enemas. Stool samples may reveal reduced pancreatic enzymes, and genetic testing confirms CFTR mutations. Meconium plug syndrome must be differentiated to rule out other causes of intestinal obstruction.

Treatment Options

Treatment includes conservative management with enemas (e.g., gastrografin) to dislodge meconium, or surgical intervention (e.g., enterotomy or resection) for severe cases. Post-treatment, pancreatic enzyme replacement and nutritional support are initiated to address malabsorption. Long-term management focuses on cystic fibrosis care, including airway clearance and infection prevention.

Prognosis and Follow-Up

Prognosis depends on early intervention and overall cystic fibrosis severity. Most infants recover with treatment but require lifelong monitoring for pancreatic insufficiency, respiratory complications, and growth issues. Regular follow-up with a multidisciplinary team (gastroenterology, pulmonology, nutrition) is essential to manage ongoing symptoms and prevent recurrence.

Complications

• Bowel perforation or necrosis.
• Short bowel syndrome (after surgical resection).
• Intestinal stricture or adhesions.
• Recurrent meconium-related obstructions.
• Increased risk of cystic fibrosis-related diabetes or liver disease.

Lifestyle & Prevention

While genetic, prenatal screening (e.g., carrier testing) may identify at-risk families. Newborns with a family history of cystic fibrosis should be monitored closely for early signs. Post-diagnosis, adherence to cystic fibrosis treatment plans, including enzyme supplementation and airway care, reduces complication risk.

When to Seek Professional Help

Seek immediate medical attention if a newborn fails to pass meconium, shows abdominal distension, vomiting, or signs of dehydration. Persistent gastrointestinal symptoms or respiratory distress in infants with cystic fibrosis also warrant prompt evaluation.

Tips for Medical Coders

Code E84.11 is specific to meconium ileus in cystic fibrosis and requires documentation of both the intestinal obstruction and underlying cystic fibrosis diagnosis. Ensure clinical notes confirm the presence of meconium ileus and its association with cystic fibrosis, as this code excludes other intestinal obstructions without cystic fibrosis. Verify that no more specific subcategory (e.g., with complications) applies before using E84.11.